Sinobiopharma,Inc. has announced that the company received a certificate for the use of Gabexatemesylate as a pharmaceutical raw material from theChinese State Food and Drug Administration (“SFDA”).Gabexate Mesylate is a serine proteinase inhibitor used therapeutically inthe treatment of pancreatitis, disseminated intravascular coagulation (DIC),and as a regional anticoagulant for hemodialysis. The drug inhibits thehydrolytic effects of thrombin, plasmin, and kallikrein, but not ofchymotrypsin and aprotinin. The company is now awaiting GMP certification to manufacture Gabexatemesylate.
